Study of APX-343A alone or with pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor confirmed by a biopsy.
- You should be at least 19 years old and in generally good health (able to care for yourself).
- You cannot have received immunotherapy or other cancer treatments (except some antiviral therapies) before this study.
- You must be willing to provide a tumor sample (either from a previous biopsy or a new one).
- You cannot have certain conditions like active autoimmune disease, brain metastases, or significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.